Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study.

ABSTRACT: Comprehensive genomic profiling (CGP) detects several classes of genomic alterations across numerous genes simultaneously and can match more patients with genomically targeted therapies than conventional molecular profiling. The current study estimated the costs of anticancer drugs and overall survival (OS) for patients who were treated with matched and unmatched therapy. Costs were estimated for patients with complete data (188 of 500 patients) from a prospective, nonrandomized study of patients with diverse refractory cancers who underwent CGP and were treated with matched or unmatched therapy. We assessed mean time to treatment failure (TTF) and mean observed OS. Patient-specific drug and administration costs were imputed for the first regimen after CGP on the basis of drug classes, uni

SUBMITTER: Chawla A 

PROVIDER: S-EPMC7446484 | biostudies-literature | 2018

REPOSITORIES: biostudies-literature